Navigation Links
The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited
Date:7/29/2014

WHEAT RIDGE, Colo., July 29, 2014 /PRNewswire/ -- The BioFusionary Corporation, Inc. (TBC), a medical technology company focused on developing a proprietary electromagnetic induction platform with aesthetic and surgical applications, today announced it entered into an agreement under which TBC will merge with Australia-based Continuation Investments Limited (COT) in an all-stock transaction.

Upon completion of the transaction, the Company will initially trade on the Australian Stock Exchange under the code COT. Concurrent with the execution of the agreement, COT will conduct a minimum $A5.0 million capital fund raise. Proceeds will be used to manufacture and market TBC's flagship product, the BioFusionary Bebe™, in the U.S. The Company's operations will remain in the U.S.

The BioFusionary Bebe received 510(K) clearance from the U.S. Food and Drug Administration (FDA) on 10 March 2014. The device uses high frequency electromagnetic induction (EMI) to generate deep heat within body tissues and is indicated for the treatment of medical conditions such as relief of pain, muscle spasms and joint contractures.

The BioFusionary Bebe is a non-invasive system intended for use in medical settings. Evidence suggests that the device creates heat in the dermal plane, a one-to-four mm thin layer of tissue rich in collagen structural fibers. TBC scientists believe the heat and subsequent cooling cause collagen and other tissue proteins to re-associate and entangle, which appears as tightening and improved appearance of the skin surface. In clinical studies, the initial tightening occurred almost immediately with continued improvement weeks later.

TBC recently entered into a manufacturing agreement with a U.S.-based specialty medical device manufacturer to produce the BioFusionary Bebe. The Company will focus on a targeted local launch in select U.S. cities in the fall of 2014 prior to a worldwide launch in 2015.

"This is a tremendously exciting time to bring a new technology to the U.S. market. We're confident our collaboration with Continuation Investments Ltd will support our robust clinical program and ambitious commercial growth plans," said Damon Cox, TBC's President and Chief Executive Officer. "We're encouraged by the strong reception we've received from the medical community here as well as from potential global business collaborators."  

Cox was named president and CEO of TBC in April 2014 following two years at Pinnacle Life Sciences, an independent consultancy he founded and directed. Prior to that, he was involved in the commercialization of several multi-million dollar products with leading Fortune 500 public and private companies. Cox brings an extensive history of contracting, pricing negotiating and policy development to his new role at TBC. Cox additionally served as an U.S. Army officer in the elite 82nd Airborne and as a Ranger Company Commander.

TBC Chairman Kevin Marchitto, PhD and TBC Director Stephen Flock, PhD are co-founders of the Company and co-inventors of the Company's technology. They have co-authored 28 issued patents with more than 20 patents pending. TBC holds multi-jurisdictional patents and patent applications to protect its core intellectual property covering its EMI technology platform and other novel products.

About The BioFusionary Corporation, Inc.

TBC has a product pipeline based on its proprietary EMI technology. Potential follow-on applications for the BioFusionary technology include use in urinary incontinence and cartilage reshaping. Pre-clinical research suggests the technology may be efficacious in tightening ligaments in the pelvic region and intestinal track as well as in cartilage reshaping for individuals with airway blockage (e.g., deviated septum, stenotic trachea) and for ear and nose reconstructions. Additionally, TBC has developed a curable synthetic medical adhesive based on elastic polymers. The adhesive, which is "cured" using TBC's EMI technology, has potential surgical applications such as sealing lung tissue after resection and wound closure in soft tissues.

Forward-Looking Statements

This information includes "forward-looking statements" of The BioFusionary Corporation ("TBC") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this information that address activities, events or developments TBC believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors TBC believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond TBC's control. Investors are cautioned any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain further FDA clearances or approvals, obtain CE Marking, cost effectively manufacture and generate revenues from the BioFusionary Bebe at a profitable price point, execute agreements required to successfully advance the Company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, TBC does not intend (and is not obligated) to update publicly any forward-looking statements. 


'/>"/>
SOURCE The BioFusionary Corporation, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals
2. Senior Executives of Cytyc Corporation, and Constitution Medical, Inc., Announce the Launch of ATON PARTNERS
3. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
4. Precision Optics Corporation, Inc. Operating Results for Six Months Ended December 31, 2012 and Recent Operating Activities
5. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
6. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
7. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
8. Precision Optics Corporation, Inc. Announces Operating Results for the First Quarter Ended September 30, 2012
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
11. MiMedx Announces Record Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):